 WESTLAKE VILLAGE, Calif., Oct. 26, 2020 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that it completed enrollment in its Phase 12b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 JAK1, in adult patients with chronic hand eczema. Arcutis has updated its projections and now anticipates announcing topline data from this trial by mid-2021. 